Virtual Event, Worldwide : 18 - 19 November 2020
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable customers to make the world healthier, cleaner and safer. We support oncology research with next generation sequencing solutions and innovative technologies for Solid Tumours testing and Liquid-Biopsy and Immuno-oncology applications.
Whether you’re looking at multiple targets or just a few, our NGS solutions combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages
The Oncomine cfDNA solutions family welcomes the new Oncomine Precision Assay on the Ion Torrent Genexus System. Get a 1-Day complete next-generation sequencing (NGS) testing workflow for both FFPE and Liquid biopsy testing. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before*.
We wish to inform scientists on how our Liquid Biopsy solutions can help them to accelerate driver and resistance mutations detection from a single tube of blood.
We invite you at our scientific session Wednesday 18th of November at 15:35 CET to listen from our collaborators their experience with our Liquid Biopsy Solution.
Exhaled breath is more than just air, it contains over 1,000 volatile organic compounds (VOC) as well as microscopic aerosol particles that provide a rich source of biological information. Like blood sampling, breath offers a non-invasive way to monitor human biology and enable the critical early detection of disease and optimization of treatments through precision medicine.
Compared to genomics and other -omics approaches, studying breath VOCs, so-called 'breathomics', reveals the current health status of cells, tissues and the microbiome. Many breath biomarkers are associated with metabolic or disease processes in the body. The ability to accurately collect and analyze them has applications in early detection, screening, prognosis and precision medicine including for patient stratification in therapy selection and treatment monitoring.
Wednesday 18 November - 15:35-16:00
Speaker: Winand N.M. Dinjens University Medical Center Rotterdam, Netherlands
"4 year experience of cfDNA NGS analysis: is it ready for a clinical setting?"
Dietary requirements (in-person events only)
Please indicate any special dietary requirements here. We will try to cater to all dietary requirements and we will write to you if there is any problem.
Sharing your details with others
Please click below if you agree we can share your name, email and postal address with participants and exhibitors, who may use them to contact you.
Please note: you have selected NOT to share your details with participants and exhibitors.
You can click above to change this.
We will use the email address in your EACR account to communicate with you. However, during the checkout process you will need to enter the name and contact details of the person paying for your registration, if this is different to your own details. Please make sure you have this information to hand.
Terms and Conditions
Please read our Membership and Events Terms and Conditions before completing your registration.
Photography and video
Please note that we will be taking photographs and video at the conference for publicity and marketing purposes. If you do not wish to take part please inform the photographer.
The EACR is grateful for the continued support of its Industry Partners: